New combo therapy aims to beat back tough lymphoma
NCT ID NCT04484012
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two treatments for mantle cell lymphoma that has returned or is not responding to standard care. Patients receive their own immune cells that have been genetically modified to recognize and attack cancer cells (CAR-T cells), along with a daily pill called acalabrutinib that blocks cancer growth signals. The study will enroll 36 participants to see if the combination is safe and how many patients achieve a complete response within 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAR-T cells (engineered immune cells) and acalabrutinib (a targeted cancer pill)
What this could lead to
If successful, this combination could offer a new treatment option for patients with mantle cell lymphoma that has come back or stopped responding to other therapies.
What could go wrong
This is a small, early-phase trial (36 people) focused on safety and initial effectiveness. The treatment may cause serious side effects, and it is not yet known if it works better than existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact